What Деприм Treats: Main Uses and Benefits

The medication is commonly used to provide symptomatic support for individuals dealing with mild, transient emotional distress. It is utilized to help ease the burden of symptoms related to mild low mood and nervous tension, and is applied in contexts marked by increased discomfort or tension.

The dry extract is commonly used as a traditional herbal medicinal product for managing symptoms related to mild low mood and tension. The medication helps address symptom clusters that may include feelings of melancholy, general apathy, inner restlessness, and stress-related irritability. By supporting the easing of these manifestations, it contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

It is often applied during phases of increased distress or when symptoms become more noticeable, offering supportive relief when functional stability becomes affected. “This supportive approach helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact

Quick Fact: Used for Managing Nervous Tension and Low Mood

Regulatory References

1. European Union herbal monograph on Hypericum perforatum

Who Can and Cannot Use Деприм (Hypericum perforatum Extract)

Official regulatory documents define strict population eligibility for Деприм, based on age, physiological status, and concurrent treatments. This product is indicated only for use by Adults and the Elderly for the supportive treatment of mild low mood and nervous tension.

Absolute Contraindications

Use is contraindicated and must be avoided by individuals with:

• Known hypersensitivity to Hypericum perforatum extract.
• Concurrent use of specific medications, including systemic cyclosporine, tacrolimus, warfarin, irinotecan, and certain anti-HIV protease inhibitors.

Use Restrictions and Non-Recommended Groups

Population Group	Regulatory Status
Children and Adolescents (under 18)	Use is not recommended (Insufficient data on safety and efficacy).
Pregnant Individuals	Use is not recommended (Insufficient clinical data).
Breastfeeding Individuals	Use is not recommended (Insufficient data).
Severe Depression	Non-Eligible (Product is only indicated for mild symptoms).

Individuals using this product must also adhere to the conditional restriction of avoiding intense UV-exposure (e.g., sun lamps, extensive sunbathing) due to the risk of phototoxic reactions.

Interactions with other medicines and products — Official Regulatory Information

The interaction profile of Деприм (Hypericum perforatum extract) is officially documented across international regulatory sources, defining mandatory restrictions for co-administration with numerous drug categories.

---

Interaction Scope

Category	Regulatory Statement Summary
Medicinal Product Categories	Anticoagulants, Immunosuppressants, Hormonal Contraceptives, Anti-HIV Agents, SSRIs, Triptans, Cardiac Glycosides, and certain Anticancer/Anticonvulsants.
Mechanistic Basis	Classified as a potent Enzyme Inducer (primarily CYP3A4, CYP2C9) and Transporter Inducer (P-glycoprotein/P-gp).
Timing-Based Rules	Mandatory discontinuation of the product is required for at least two weeks prior to scheduled surgical procedures.
Constraints/Severity	Interactions are frequently classified as Major/Contraindicated due to the high risk of therapeutic failure or serious adverse effects.

---

Resulting Interaction Structure

Official regulatory statements document that co-administration is contraindicated with Immunosuppressants (e.g., Cyclosporin) and Anti-HIV Agents (e.g., Indinavir) because the product reduces their plasma concentration, risking therapeutic failure. The Enzyme and Transporter Induction effects result in significantly decreased exposure for numerous substrate medications, including Hormonal Contraceptives (risk of unintended pregnancy) and Anticoagulants (risk of reduced efficacy). A pharmacodynamic interaction with serotonergic agents (e.g., SSRIs) is also documented, leading to the risk of Serotonin Syndrome. These documented constraints mandate formal restrictions on co-administration with critical substrate medicines.

How Деприм Works: The Mechanism of Action

The effect of Деприм (Standardized Hypericum perforatum extract) is based on a multimodal pharmacodynamic profile within the central nervous system, primarily driven by the compound Hyperforin. The mechanism operates across three key biological domains to promote alterations in neuronal signaling.

---

Modulating Neurotransmitter Availability via Ion Channels

The core mechanism involves the indirect inhibition of neurotransmitter reuptake for serotonin (5-HT), norepinephrine (NE), and dopamine (DA). Hyperforin initiates this process by activating the TRPC6 ion channel on the presynaptic membrane. This molecular step alters the cell's ion balance, leading to functional inhibition of the SERT, NET, and DAT transporters from clearing neurotransmitters from the synaptic space. This sustained increase in available chemical messengers modifies neurochemical signaling within central pathways.

---

Neuroreceptor Adaptation and Homeostasis

The prolonged elevation of neurotransmitter levels drives essential long-term receptor adaptation. Nerve cells gradually adjust the sensitivity and expression of post-synaptic receptors, such as beta-adrenergic receptors. This necessary biological re-calibration of the neural network reflects the time-dependent modulation of central pathways.

---

Systemic Support and Multimodal Synergy

The overall physiological effect is supported by the synergy of the full extract, including Flavonoids and Hypericin. These auxiliary components contribute to the mechanism through weak inhibition of Monoamine Oxidase (MAO) enzymes and by providing neuroprotective support. These actions help limit the impact of excessive mediator activity and influences the regulation of pathways associated with neurobiological response to stress.

The administration of the standardized Hypericum perforatum extract (Деприм) follows a specific oral regimen. The method of administration is oral use, typically involving swallowing a tablet or capsule whole with a sufficient amount of liquid, such as water. Administration timing is generally independent of mealtimes, allowing for flexibility in the daily schedule.

The standard adult dosing regimen is often set at 600 mg of the standardized dry extract per day. This total dose is typically achieved by administering a 300 mg unit strength twice daily, usually once in the morning and once in the evening. Depending on the specific formulation, the total daily dose may reach 900 mg. This consistent daily frequency is crucial for maintaining the steady intake required over the course of treatment.

Regarding the course of treatment, the preparation is used continuously for a period of at least two to four weeks before the full intended effect is observed. Treatment courses often continue for up to six weeks for traditional use. For population-specific use, the product is not recommended for children under the age of 12 due to insufficient data supporting its administration in this group. If a dose is missed, it is generally advised against taking a double dose; the next scheduled dose should be taken at the usual time.

Research Evidence / Overview of Studies for Деприм

---

Evidence for Mild Low Mood and Nervous Tension

Research into standardized St. John's wort extracts was studied for Randomized Controlled Trials (RCTs), which is the primary focus of the research base. These short-term studies, along with subsequent meta-analyses that combine their results, contribute to the evidence landscape. These studies were designed to measure changes in symptom intensity, using clinician-rated scales like the Hamilton Depression Rating Scale (HAM-D) to monitor how low mood and associated nervous tension were observed over a typical study period of 6 to 12 weeks.

Measurements reported in these large-scale reviews and analyses were observed when comparing participants receiving the extract versus those receiving an inactive substance (placebo). Other research has explored measurements from trials where the extract was studied using certain standard pharmaceutical options in research contexts involving fluctuating or unstable symptoms. Research highlights changes measured during the study period. Studies report how symptoms evolved in the observed populations, but findings were mixed due to substantial variation across different trials.

Study Design and Measured Outcomes

The research exploring this extract was structured to monitor how symptoms change over time. Studies focused on outcomes related to functional imbalance and daily functioning, but the primary focus was on symptom severity. This involved research examining physiological strain or stress and monitoring outcomes related to observed changes (the percentage of participants reaching a predefined threshold of symptom score reduction). Research provides insight into short-term changes observed in the trial settings.

---

Research on Other Symptomatic Uses

Studies have also explored contexts involving fluctuating or episodic manifestations, specifically applied in research contexts involving fluctuating or unstable symptoms associated with Premenstrual Syndrome (PMS). However, the evidence is limited for this application. The studies were typically smaller, short-term RCTs that focused on outcomes related to physical discomfort and outcomes describing episodic changes over two to three menstrual cycles.

---

Long-Term Evidence and Maintenance Studies

Most of the research structure for the extract comes from studies focused on acute treatment, typically covering time intervals of 6 to 12 weeks. This acute research exploring short-term symptom changes contributes to the broader evidence landscape regarding initial use.

Long-term effects are not fully established, and there is limited information for outcomes related to treatment maintenance. Studies examining the durability of effect and the potential for preventing symptoms from recurring over extended periods (e.g., six months or longer) are less common than the short-term efficacy trials. Research provides context but not individual predictions regarding long-term response.

---

Evidence in Specific Patient Populations

Data for certain groups remain insufficient. Specifically, individuals experiencing severe depression are typically excluded from these trials, meaning the available research provides limited insight for this specific population. Similarly, there is limited information regarding the effects in adolescents, children, or older adults, as these groups are generally underrepresented or not included in the core efficacy studies.

---

Research Gaps and Areas of Uncertainty

Evidence highlights what is known, and also what is still uncertain. One key limitation is the variability across studies, which may be related to differences in the specific extraction and standardization methods of the Hypericum perforatum product being evaluated. Subgroup findings are uncertain, as the results apply primarily to the specific populations studied, and data are still emerging for uses beyond mild low mood.

Key Studies & References

1. A meta-analysis on the efficacy and safety of St John's wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults

Common questions about Деприм (FAQ)

---

Q: What is Деприм used for besides what is listed on the package?

Official regulatory approval for this product is limited to the supportive treatment of mild low mood and nervous tension. Studies have also examined the use of the active ingredient for other conditions, such as Premenstrual Syndrome (PMS). However, the available research may not be sufficient for regulatory approval beyond the primary indicated uses.

Q: Do older adults need a different amount of Деприм?

Official product information indicates that Деприм is intended for use by both Adults and the Elderly. The regulatory documents generally state the standard adult dose applies to the elderly population as well. Any potential dosage adjustment is typically managed under the guidance of a qualified healthcare professional.

Q: Does Деприм lose its effectiveness over time?

Studies examining the durability of the product's effect over extended time periods are limited. Most research focuses on short-term use, typically between 6 to 12 weeks. Therefore, the long-term maintenance of the effect has not been fully established in official research summaries.

Q: Is Деприм safe for long-term use?

Official research and regulatory data primarily focus on acute use, which is typically over a period of 6 to 12 weeks. Consequently, the long-term safety profile and effects of continuous use extending past this time frame are not fully established in the available regulatory documents.

Q: What are the most commonly reported side effects of Деприм?

Regulatory documents report that common types of side effects include gastrointestinal symptoms, headache, fatigue, and allergic skin reactions. However, for most non-serious side effects, the official information explicitly states that a reliable estimate of their frequency (how often they happen) is not known from the available data.

Q: What are the signs that Деприм is starting to work?

The full intended effect is generally observed after two to four weeks of continuous use. According to regulatory descriptions, the product is intended to provide an easing of nervous tension and help stabilize a mildly lowered mood. Observed changes are typically monitored by a healthcare professional.

Q: Why is the dosage different for different people?

Official regulatory documents generally establish a standard daily intake for adults. However, some official monographs permit a higher total daily dose, for example, up to 900 mg, depending on the specific product formulation and the guidance issued by various health authorities.

Q: Can Деприм cause weight gain?

Weight gain is not explicitly documented as a specific adverse reaction in the regulatory safety information. Reported side effects primarily relate to nervous system and gastrointestinal disorders. Any significant changes in health status are typically reviewed by a healthcare professional.

Q: Does Деприм make you feel drowsy or sleepy?

Official regulatory information lists fatigue and dizziness as nervous system disorders that have been reported with the use of the product. The specific terms drowsiness or sleepiness are not typically used in the official adverse reaction lists.

Q: Can I take Деприм if I am also taking vitamins or supplements?

The official regulatory interaction profile focuses heavily on documented interactions with other medicinal products due to the herb's effect as an enzyme inducer. Interactions with all vitamins and supplements are not fully or consistently monitored in the official regulatory texts. It is generally necessary to have all co-administered supplements reviewed by a qualified professional.

Q: Can Деприм interact with common pain relievers like ibuprofen?

Official regulatory information cautions against use with medicines metabolized by certain enzymes (like CYP450). However, common non-prescription pain relievers such as ibuprofen are not typically listed among the major contraindicated drugs in the primary regulatory documents. The suitability of co-administering any medicines is a topic for discussion with a healthcare professional.

Q: Can I drink coffee or caffeine while taking Деприм?

Official regulatory documents do not list caffeine or coffee as a formal interaction. However, the product affects neurotransmitter levels in the central nervous system. As a general precaution, substances that also affect the central nervous system may be used with caution due to the potential for compounded effects.

Q: Is it okay to drive or operate machinery after taking Деприм?

Regulatory texts advise awareness because the product has been associated with effects such as fatigue and dizziness, which are classified as nervous system disorders. These types of reactions may impair a person's ability to safely operate machinery or drive vehicles.

Q: Do I need to change my diet while using Деприм?

Official product information does not mandate any general dietary changes while using the product. Administration is generally described as being independent of mealtimes.

Q: Are there any specific foods I should avoid while on Деприм?

The official regulatory documentation does not include instructions requiring the avoidance of any specific foods or drinks.

Q: Does Деприм have a risk of withdrawal if I stop taking it suddenly?

Official safety information does not specifically document a withdrawal risk for the herbal extract itself. However, regulatory texts warn that upon stopping treatment, blood levels of any co-administered interacting medicines may increase, which carries a risk of potential delayed toxicity from those other medicines.

Q: Does taking Деприм with food reduce side effects?

Official administration instructions state that the product is generally taken independently of mealtimes. Regulatory documents do not provide specific guidance or instruction on taking the product with food for the purpose of reducing side effects.

Q: Can Деприм affect my ability to concentrate?

The regulatory label documents effects under Nervous System disorders, which include restlessness and fatigue. While the official text does not explicitly mention concentration, these reported effects are noted as general changes in central nervous system function.

Q: Are there any known interactions between Деприм and cold medicine?

Official warnings highlight interactions with medicines that are metabolized by specific enzymes. Cold medicines are a broad category of products and are not specifically listed as a contraindicated class in the official drug interaction documents. Confirming the components of any cold medicine is necessary prior to co-administration.

Q: How is the safety of Деприм monitored after it's approved?

Once approved, the safety of the product is monitored by regulatory authorities through pharmacovigilance programs. This requires the continuous reporting of suspected adverse reactions and interactions from healthcare professionals and patients to ensure the ongoing assessment and safety monitoring of the product.

How to Store and Dispose of Деприм (St. John's Wort)

The storage of Деприм must adhere strictly to official regulatory conditions to maintain product stability and potency. The tablets must be stored at a temperature not exceeding 25 °C and must be protected from both light and moisture. To achieve this, the product must be kept in its original container and the container must remain tightly closed.

Required Storage and Disposal

Requirement	Official Statement
Temperature	Store below 25 °C.
Protection	Protect from light and moisture.
Child Safety	Keep out of the sight and reach of children.
Disposal	No special product-specific requirements; dispose of unused medicine according to local regulations (e.g., drug take-back programs).

The medicine must not be used after the expiry date printed on the packaging.